Suggestions
Ramji Srinivasan
Ramji Srinivasan is the cofounder and CEO of Teiko.bio, a biotechnology company focused on immune profiling for clinical trials.12 He has a background in entrepreneurship and technology, with previous experience in the healthcare industry.
Education and Early Career
Ramji holds a B.S. in Computer Science and an M.S. in Financial Mathematics, both from Stanford University.23 He also attended Stanford's Graduate School of Business but dropped out to pursue entrepreneurial ventures.2
Entrepreneurial Experience
Before founding Teiko.bio, Ramji was the cofounder, CEO, and Chairman of Counsyl, a women's health genetic screening laboratory.34 Under his leadership, Counsyl screened over 1 million prospective parents, mothers-to-be, and women at risk of hereditary cancer. In 2018, Counsyl was acquired by Myriad Genetics, Inc. for $375 million in cash and stock.3
Current Role at Teiko.bio
At Teiko.bio, Ramji leads a team of PhD-trained experts in Immunology and Bioinformatics.3 The company's mission is to make immune profiling a reality for clinical trials and eventually for patients.2 Teiko.bio uses high-dimensional cytometry, both spectral and mass, to measure the immune state of patients in clinical trials.5
Ramji's expertise in technology and healthcare, combined with his entrepreneurial experience, positions him well to lead Teiko.bio in its goal of advancing immune profiling technologies for clinical applications.
Highlights
Immunotherapy isn't just T cells:
"Mahadevan et al. report that pancreatitis leads to the recruitment of a class of immune cells called conventional dendritic cells that can help to protect tissue from self-destruction by T lymphocytes. They found that the coexistence of pancreatitis and pancreatic cancer resulted in an aggressive disease in which conventional dendritic cells influenced a suppressive T cell subset to override the action of T cells that usually destroy cancer. Blocking the suppressor T cells with immunotherapy reduced the growth of pancreatic cancer. Therefore, engineered cancer-specific conventional dendritic cells along with immunotherapy may provide a mechanism to intervene in pancreatic cancer."
Teiko.bio Scientist and Research Openings available; apply today or DM if interested talking more!
We are powering immune analysis for real-life 500+ specimen clinical trials in immunotherapy. This role is intended for someone interested in working at the intersection of immunology, data science, and high-speed lab operations.
Sounds interesting to you? Read on.
https://lnkd.in/gbhp-8MD https://lnkd.in/gSHAva_r
